(Q38125952)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Renal safety in patients treated with bisphosphonates for osteoporosis: a review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

0 references

Paul D Miller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Sophie A Jamal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Pieter Evenepoel

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

Journal of Bone and Mineral Research

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

2049-2059

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23907861%20AND%20SRC:MED&resulttype=core&format=json

Prediction of creatinine clearance from serum creatinine

6 March 2020

cites work

1 reference

Relationship between age, renal function and bone mineral density in the US population

21 January 2018

1 reference

Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).

21 January 2018

1 reference

Bisphosphonates: the first 40 years

21 January 2018

1 reference

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

21 January 2018

1 reference

Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety

21 January 2018

1 reference

Renal secretion of diphosphonates in rats

21 January 2018

1 reference

Drug-associated renal dysfunction and injury

21 January 2018

1 reference

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

21 January 2018

1 reference

Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases

21 January 2018

1 reference

Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma

21 January 2018

1 reference

Preclinical perspectives on bisphosphonate renal safety

21 January 2018

1 reference

Anticancer drug-induced kidney disorders

21 January 2018

1 reference

Cancer and renal insufficiency results of the BIRMA study.

21 January 2018

1 reference

Renal insufficiency and failure

21 January 2018

1 reference

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials

21 January 2018

1 reference

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

21 January 2018

1 reference

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

21 January 2018

1 reference

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

21 January 2018

1 reference

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

Fracture risk and zoledronic acid therapy in men with osteoporosis

21 January 2018

1 reference

Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study

21 January 2018

1 reference

Renal function and risk of hip and vertebral fractures in older women.

21 January 2018

1 reference

Association of kidney function with incident hip fracture in older adults.

21 January 2018

1 reference

Fracture risk assessment in patients with chronic kidney disease

21 January 2018

1 reference

Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy

21 January 2018

1 reference

The kidney and bisphosphonates

21 January 2018

1 reference

Discriminants of prevalent fractures in chronic kidney disease

21 January 2018

1 reference

BMD and fracture risk in CKD: where should we go from here?

21 January 2018

1 reference

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

21 January 2018

1 reference

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

21 January 2018

1 reference

FGF-23: More than a regulator of renal phosphate handling?

21 January 2018

1 reference

Osteoporosis and adynamic bone in chronic kidney disease

21 January 2018

1 reference

Renal osteodystrophy, phosphate homeostasis, and vascular calcification

21 January 2018

1 reference

Arterial calcification and bone physiology: role of the bone-vascular axis

21 January 2018

1 reference

Arterial calcifications and bone histomorphometry in end-stage renal disease

21 January 2018

1 reference

Adynamic bone disease: clinical and therapeutic implications.

21 January 2018

1 reference

Bone and kidney disease: diagnostic and therapeutic implications

21 January 2018

1 reference

PTH--a particularly tricky hormone: why measure it at all in kidney patients?

21 January 2018

1 reference

High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine

21 January 2018

1 reference

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment

21 January 2018

1 reference

Assessing kidney function--measured and estimated glomerular filtration rate

21 January 2018

1 reference

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP).

21 January 2018

1 reference

Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III).

21 January 2018

1 reference

Fragility fractures in chronic kidney disease: an opinion-based approach

21 January 2018

1 reference

Oral bisphosphonate use in the elderly is not associated with acute kidney injury

21 January 2018

1 reference

A predictive model for progression of chronic kidney disease to kidney failure

21 January 2018

1 reference

Bisphosphonate nephrotoxicity

21 January 2018

1 reference

Benefits and risks of bisphosphonate therapy for osteoporosis

21 January 2018

1 reference

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday

21 January 2018

1 reference

Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial

21 January 2018

1 reference